The Covovax COVID-19 vaccine is being tested in phase 2/3 trials in children aged 7 to 11 at Pune’s Bharati Vidyapeeth Medical College and Hospital.
The Covid vaccination study for children began in India, and the age bracket for enrollment is 2-17 years. COVOVAX is the Indian version of the NOVOVAX vaccination for children, which was introduced in India by the Serum Institute of India.
“Pune’s Bharati Vidyapeeth Medical College Hospital began phase 2/3 trials of Covovax in children between 7 and 11 years of age. Nine children have been enrolled for the trial here,” said Dr Sanjay Lalwani, the Medical Director of the hospital, as quoted by news agency ANI.
“For the children who wish to enrol their parents are counselled in local vernacular language and the audiovisual consulting process is documented. Once the parents give their consent, then the volunteer is subjected to an RT PCR test and an antibody test. Although, this does not stop them from being a part of the trial,” he added.
As many as nine centres have been identified across India for this phase, including Bharati Vidyapeeth Medical College Hospital.
“In paediatric, it’s an age de-escalation trial; which means that you start with children of higher age and see the efficacy, and then proceed to the lower ages. So, part one is between the 11-17 age group where 100s have been enrolled in India. There are 9 sites in India and approx 1,000 children will enrol across the county. We at our site have started the trial for the age group of 7-11,” Lalwani said.
During the trial, two doses at a gap of 21 days will be administered.
